In the current work we show how metformin acts upon preosteoblasts to increase the subsequent adhesion of myeloma cells, with this indirect effect on myeloma cells dependent, at least in part, upon elevated OPN levels in metformin-treated preosteoblasts. The gene discussed is SPP1; the disease is plasma cell myeloma.